Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
TelyRx Holdings Inc. is a publicly listed healthcare services company focused on telepharmacy and digital healthcare delivery. The company operates at the intersection of healthcare services, pharmaceutical dispensing, and telemedicine-enabled care, with an emphasis on improving patient access to prescription medications through virtual-first models. Its core value proposition centers on integrating licensed pharmacy services with online clinical workflows to streamline prescribing, fulfillment, and patient engagement.
Founded in the early 2020s, TelyRx was established to address access and efficiency gaps in traditional pharmacy distribution, particularly for patients underserved by brick-and-mortar pharmacies. The company has evolved from a single telepharmacy platform into a broader digital healthcare services provider supporting remote prescribing and medication fulfillment across regulated markets. Public disclosures describe its positioning as a technology-enabled healthcare operator rather than a pure software provider.
Business Operations
TelyRx generates revenue primarily through telepharmacy services, which include prescription processing, medication dispensing, and fulfillment tied to virtual care encounters. Its operations are structured around regulated pharmacy assets, digital patient interfaces, and clinical workflow technologies that support prescribers and pharmacists. Revenue is derived from prescription volume, service agreements, and pharmacy-related professional fees, subject to jurisdictional healthcare regulations.
The company operates through licensed pharmacy entities and affiliated healthcare service providers, supporting both domestic and cross-border operations where permitted. TelyRx controls proprietary digital infrastructure that connects prescribers, pharmacists, and patients, while maintaining compliance with pharmacy and healthcare regulations. Public filings reference partnerships with healthcare providers and platform integrations, though details on joint ventures or material subsidiaries beyond regulated pharmacy entities are limited. Data inconclusive based on available public sources regarding the full scope of subsidiaries.
Strategic Position & Investments
TelyRx’s stated strategy emphasizes scalable growth in virtual pharmacy-enabled care, leveraging regulatory-compliant pharmacy licenses and digital platforms to expand prescription access. Growth initiatives have focused on increasing prescription volume, entering new regulated markets, and enhancing platform capabilities to support additional therapeutic areas and clinical use cases.
The company has disclosed investments in technology infrastructure and licensed pharmacy assets as key components of its expansion strategy. While management has referenced potential acquisitions and market entry opportunities in public communications, confirmed details of major completed acquisitions or material portfolio investments beyond core pharmacy operations are limited. Data inconclusive based on available public sources regarding significant acquisitions or emerging technology investments outside telepharmacy.
Geographic Footprint
TelyRx is headquartered in Canada, with operational and investment exposure extending into North America, including regulated activities connected to the United States healthcare market. Its geographic footprint is defined by the jurisdictions in which it holds or partners for licensed pharmacy operations, rather than by a large physical retail presence.
The company’s international influence is primarily operational rather than capital-intensive, relying on digital platforms and regulated healthcare entities to serve patients across borders where legally permitted. Public disclosures emphasize a focus on expanding market presence in developed healthcare systems with established telehealth and pharmacy regulatory frameworks.
Leadership & Governance
TelyRx was founded by a physician-entrepreneur with a strategic vision centered on increasing access to care through regulated digital health infrastructure. The leadership philosophy, as reflected in public filings, emphasizes compliance-first growth, clinician-led decision-making, and technology-enabled scalability within healthcare regulations.
Key executives include:
- Dr. Danial Bahrami – Founder and Chief Executive Officer
- Navid Hakimi – Executive Officer (specific title publicly reported; exact scope of responsibilities inconclusive based on available public sources)
The company is governed by a board of directors with experience in healthcare, finance, and public company oversight. Detailed disclosures regarding additional executive roles and governance committee structures are limited in publicly available summaries.